Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Clinical trial NCT01024946 · COMPLETED
Trial details
- NCT number
- NCT01024946
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-12-01
- Primary completion
- 2012-07-01
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.